Definium's LSD depression drug DT120 ODT shows best-in-class Phase 3 results
Definium Therapeutics reports topline Phase 3 results for its LSD-based antidepressant DT120 ODT in the 149-patient Emerge trial, showing an 8.1-point placebo-adjusted MADRS reduction at six weeks and a 7.1-point reduction at 12 weeks, with no new safety signals; the company is running a 40-week open-label extension, and has additional Phase 3 readouts for anxiety and depression expected later this year as it charts a potential path to approval for treatment-resistant depression.